Baxter (BAX) Healthcare Announces Licensing Agreement with Innocoll for Gentamicin Surgical Implant
More News related to BAX
- Relational Investors Raises Stakes In Yahoo! (YHOO) and Sun Microsystems (JAVA), Shows New Stake In Schering-Plough (SGP)
- Baxter International (BAX) Boosts Qt Dividend 20% to $0.26/Sh
- Baxter Declares Quarterly Dividend, Increases Rate 20 Percent
- AmeriCares Launches India Operations
- Baxter to Present at the 2008 Annual Credit Suisse Health Care Conference
More News related to Corporate News
- Honda Develops Ecological Drive Assist System for Enhanced Real World Fuel Economy
- With More Items, Bigger Savings and Better Deals Than Ever, Toys"R"Us Unleashes Unprecedented Black Friday Weekend Mega Event
- New Website Aimed at Helping Millions of Teens Growing up Without a Father
- PR Newswire Broadcast Minute for Thursday November 20, 2008
- Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
Baxter (NYSE: BAX) Healthcare Corporation today announced a licensing agreement with Innocoll Pharmaceuticals Ltd, granting Baxter exclusive rights to market and distribute the company's gentamicin surgical implant in the United States.
The gentamicin surgical implant will be the first and only biodegradable, leave-behind antibiotic surgical sponge used as an adjunct (add-on) therapy for prevention and treatment of surgical site infections in the United States. This agreement is expected to add to Baxter's biosurgical portfolio by giving surgeons an innovative option to help reduce risk of post-operative complications of SSIs during surgery.
Baxter International, Inc. operates as a healthcare company worldwide.
Related Categories
Corporate NewsStocks Mentioned
-3.93Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
